Комбинированная фармакотерапия артериальной гипертензии

1. Беленков Ю.Н. и др. Эналаприл плюс индапамид в лечении стабильной артериальной гипертонии: оценка эффективности и безопасности рациональной комбинированной терапии. Сердце 2005; 4 (5): 277–86.
2. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
3. Мартынюк Т.В., Колос И.П., Чазова И.Е. от имени соисследователей программы СТРАТЕГИЯ. Эффективность и безопасность фиксированной комбинации малых доз периндоприла/индапамида у пациентов с артериальной гипертонией в условиях реальной практической практики. Кардиоваск. тер. и проф. 2007; 6 (8): 21–7.
4. Advance Collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomesin patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
5. Chalmers J et al. Long-term efficacy of a new fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first line therapy in elderly hypertensive patients. J Hypertension 2000; 18; 327–31.
6. Danhlo..f B, Gosse P. on behalf of the PICXEL investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertension 2005; 11: 2063–70.
7. Danhlo..f B et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumetiazide as required, in the anglo-Scandinavian cardiac outcomes trial blood pressure lowering arm: a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
8. Danhlo..f B et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
9. De Luca N. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertension 2004; 8: 660–7.
10. Dogrell SA. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Lancet 2003; 361: 117–24.
11. ESH-ESC Guidelines Committee. 2007 guidelines for management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
12. Frishman W.N. et al. A multifactorial trial desigh to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461–8.
13. Gosse P et al. Efficacy of very low dose perindopril 2 mg/indapamide 0,625 mg combination on leftventricular hypertrophy in hypertensive patients: the PICXEL study rationale and design. J Hum Hypertension 2002; 9: 653–9.
14. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62.
15. Joshi SR et al. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial). J Assoc Physicians India 2004; 52: 189–95.
16. Kjeldsen SE et al Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17 (1): 7–17.
17. Lindholm LH et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertension 2003; 21 (8): 1563–74.
18. Mogensen CE et al. Effect of a low dose Perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71.
19. Mogensen CE et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.
20. Mourad JJ et al. on behalf of the investigators of the STRATHE trial. Comparision of different therapeutic strategies in hypertension: a low-dose combination of low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004; 22: 2379–96.
21. Mourad JJ et al. What rates of blood pressure normalisation can be expected from a first-line combination therapy in the real life? The OPTIMAX study. Eur Heart J 2006; 27 (Suppl): 298: Abst 1792.
22. Pepine CJ et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronaryartery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805–16.
23. PROGRESS collaborative group. Randomised trial of perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
24. Ruggenenti P et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
25. Ruilope L, Zanchetti A. Targeting hypertension with valsartan : Lessons learned from the valsartan/HCTZ versus amlodipine in stage II hypertensive patients (VAST) trial J of the renin-angiotensin-aldosterone system 2006; 7: S1.
26. Scholze J et al. Optimal treatment of obesity-related hypertension : The hypertension-obesity-sibutramine (HOS) study. Circulation 2007; 115 (15): 1991–98.
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and micro vascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
28. Yusuf S et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.

Т.Е.Морозова, Т.Б.Андрущишина